Skip to main content
Evan Yu, MD, Oncology, Seattle, WA, UW Medicine/Harborview Medical Center

EvanYa-WenYuMD

Oncology Seattle, WA

Associate Professor, Medicine, University of Washington School of Medicine

Dr. Yu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Yu's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2004
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1998 - 2001
  • University of Washington School of Medicine
    University of Washington School of MedicineClass of 1998

Certifications & Licensure

  • WA State Medical License
    WA State Medical License 2004 - 2025
  • MT State Medical License
    MT State Medical License 2021 - 2025
  • MA State Medical License
    MA State Medical License 2000 - 2005
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Association of Clonal Hematopoiesis in DNA Repair Genes with Prostate Cancer Plasma Cell-Free DNA Testing Interference  
    Michael T Schweizer, Petros Grivas, Heather H Cheng, Evan Y Yu, JAMA Oncology
  • Undetectable Prostate‐Specific Antigen After Short‐Course Androgen Deprivation Therapy for Biochemically Recurrent Patients Correlates with Metastasis‐Free Survival an...  
    Heather H Cheng, Jonathan T Wingate, Evan Y Yu, The Prostate

Lectures

  • Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYN... 
    2019 ASCO Annual Meeting - 6/1/2019
  • A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carci... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Targeted Therapies in Advanced Urothelial Cancer 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • Kineta Appoints Internationally-Renowned Clinical Immuno-Oncology Experts to Its Scientific Advisory Board
    Kineta Appoints Internationally-Renowned Clinical Immuno-Oncology Experts to Its Scientific Advisory BoardMarch 1st, 2023
  • What Is Phenotypic Precision Medicine and Its Role in GU Oncology? – Part 1
    What Is Phenotypic Precision Medicine and Its Role in GU Oncology? – Part 1May 18th, 2022
  • What Is Phenotypic Precision Medicine and Its Role in GU Oncology? – Part 2
    What Is Phenotypic Precision Medicine and Its Role in GU Oncology? – Part 2May 18th, 2022
  • Join now to see all

Professional Memberships

Other Languages

  • Chinese (Mandarin)

Hospital Affiliations